IGF-1 LR3 Research Guide (Preclinical Overview)
This research guide provides analytical investigators with a comprehensive overview of Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3). Synthesized specifically for laboratory evaluation and in vitro cell culture systems, this recombinant analog features structural modifications designed to alter binding protein affinity and extend biological persistence. Here, we outline its molecular architecture, primary signaling pathways, preclinical model data, and laboratory handling protocols.
Quick answer
This research guide provides analytical investigators with a comprehensive overview of Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3). Synthesized specifically for laboratory evaluation and in vitro cell culture systems, this recombinant analog features structural modifications designed to alter binding protein affinity and extend biological persistence. Here, we outline its molecular architecture, primary signaling pathways, preclinical model data, and laboratory handling protocols.
Key takeaways
- Long R3 Insulin-Like Growth Factor-1 ([IGF-1 LR3](/research-peptides/igf-1-lr3)) is an 83-amino-acid synthetic analog of human insulin-like growth factor 1.
- In cell culture media and extracellular environments, native growth factors are bound by high-affinity binding proteins that regulate bio-availability and neutral clearance.
- Binding of [IGF-1 LR3](/research-peptides/igf-1-lr3) to the heterotetrameric IGF-1R extracellular domain induces autophosphorylation of intracellular tyrosine residues.
- To select the appropriate analog for specific experimental paradigms, investigators frequently evaluate structural variations across the insulin-like growth factor superfamily.
Molecular Structure and Discovery of Long R3 IGF-1
Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3) is an 83-amino-acid synthetic analog of human insulin-like growth factor 1. Native IGF-1 consists of a single 70-amino-acid polypeptide chain stabilized by three intra-chain disulfide bonds. In contrast, the engineered variant IGF-1 LR3 incorporates two specific structural alterations: the substitution of Glutamic Acid (Glu) with Arginine (Arg) at position 3, and a 13-amino-acid N-terminal extension peptide (Met-PFP-extension).
These alterations were engineered during early recombinant protein studies to overcome a primary physiological constraint observed in mammalian tissue cultures: the rapid sequestration of native IGF-1 by endogenous IGF-Binding Proteins (IGFBP-1 through IGFBP-6). By introducing a basic residue at position 3 and extending the amino terminus, researchers effectively altered the electrostatic charge and spatial conformation of the N-terminal region. Consequently, in vitro assays demonstrate that IGF-1 LR3 exhibits a dramatic reduction in affinity for inhibitory binding proteins while retaining full agonistic potential at the cell-surface Type 1 IGF Receptor (IGF-1R).
IGF Binding Protein Kinetics and Receptor Interactions
In cell culture media and extracellular environments, native growth factors are bound by high-affinity binding proteins that regulate bio-availability and neutral clearance. Native IGF-1 binds to IGFBPs with equilibrium dissociation constants ($K_d$) in the sub-nanomolar range, frequently limiting the concentration of free, active ligand capable of interacting with cell surface receptors.
Preclinical binding assays indicate that the Arg3 modification and N-terminal tail reduce the binding affinity of IGF-1 LR3 for IGFBPs by up to 1,000-fold compared to wild-type sequences. Because the analog does not readily form stable complexes with circulating or secreted IGFBPs, a significantly higher proportion of the peptide remains in an unbound, bioactive state. This structural alteration extends the operational half-life of the molecule in liquid assay media, facilitating sustained stimulation of target cell lines in longitudinal in vitro experiments.
Intracellular Signal Transduction Pathways
Binding of IGF-1 LR3 to the heterotetrameric IGF-1R extracellular domain induces autophosphorylation of intracellular tyrosine residues. This enzymatic activation triggers two primary intracellular cascade pathways commonly monitored in cell biology laboratories: the Phosphoinositide 3-Kinase (PI3K) / Akt pathway and the Mitogen-Activated Protein Kinase (MAPK) / ERK pathway.
Activation of the PI3K/Akt pathway by IGF-1 LR3 initiates downstream signaling events involving mammalian target of rapamycin (mTORC1) and glycogen synthase kinase-3 beta (GSK-3β). In vitro experiments utilizing immortalized myoblast lines (such as C2C12 cells) indicate that Akt activation promotes protein translation through S6 kinase 1 (S6K1) and 4E-BP1 phosphorylation, while simultaneously inhibiting ubiquitin-proteasome-mediated proteolytic pathways. Concurrently, signaling through the MAPK/ERK cascade regulates transcription factors responsible for cellular proliferation, cell cycle progression, and anti-apoptotic gene expression.
Comparative Analysis of IGF Analog Variants
To select the appropriate analog for specific experimental paradigms, investigators frequently evaluate structural variations across the insulin-like growth factor superfamily. While native IGF-1 serves as the baseline physiological control, its short half-life in non-supplemented media (often under 30 minutes) necessitates frequent re-dosing or continuous perfusion systems.
Conversely, truncated analogs such as IGF-1 DES lack the first three N-terminal residues entirely (tripeptide deletion), rendering them highly potent in localized target tissues but rapidly cleared in systemic rodent models. Another related growth factor pathway modulator, PEG-MGF, utilizes a C-terminal splice variant domain coupled to a polyethylene glycol moiety to isolate localized tissue remodeling signals without cross-reacting directly with systemic metabolic clearance mechanisms. Among these variants, IGF-1 LR3 remains the benchmark peptide for long-acting, generalized receptor engagement in extended tissue culture models.
In Vitro Research Applications and Cell Line Models
In laboratory settings, IGF-1 LR3 is utilized across diverse preclinical research models to investigate cellular growth, metabolism, and differentiation. In myoblast cell culture studies, the peptide is frequently added to differentiation media to accelerate the fusion of mononucleated satellite cells into multinucleated myotubes, enabling researchers to map structural protein assembly and cytoskeletal dynamics.
Furthermore, researchers utilize IGF-1 LR3 to study metabolic signaling, specifically glucose uptake kinetics and amino acid transport across lipid membranes in hepatocytes, adipocytes, and skeletal muscle explants. In neural stem cell assays, in vitro exposure to IGF-1 LR3 has provided insights into neurotrophic signaling, neurite outgrowth, and cellular survival under induced oxidative stress parameters.
Synthesis, Recombinant Expression, and Chemical Characterization
High-purity IGF-1 LR3 is typically produced via recombinant DNA technology using *Escherichia coli* expression systems, followed by high-performance liquid chromatography (HPLC) purification and refolding steps to ensure native disulfide bond formation. Because improper folding can lead to biological inactivation or aggregation, rigorous analytical verification is necessary prior to experimental deployment.
At PX1 Research, every lot of USA-synthesized research-grade peptide undergoes exhaustive third-party analytical testing. High-Performance Liquid Chromatography (HPLC) is employed to confirm chemical purity levels exceeding 98%, while Mass Spectrometry (MS) verifies the precise molecular mass (8,380 Da). Detailed documentation for every lot is maintained in our accessible research library.
Laboratory Reconstitution and Handling Standards
Lyophilized IGF-1 LR3 should be stored at -20°C or -80°C upon receipt to maintain long-term peptide stability. Prior to reconstitution, vials should be brought to room temperature in a desiccated environment to prevent moisture condensation within the container.
For laboratory reconstitution, researchers commonly utilize dilute acetic acid (0.1 M, pH 2.0 to 3.0) or sterile 10 mM hydrochloric acid to achieve complete solubilization, as basic or neutral unbuffered solutions may induce peptide aggregation. Once initial solubilization is achieved, the solution can be further diluted into sterile phosphate-buffered saline (PBS) or cell culture media containing 0.1% Bovine Serum Albumin (BSA) or human serum albumin as a carrier protein to prevent non-specific adsorption to plasticware.
Procurement and Institutional Supply
PX1 Research provides high-purity recombinant proteins and synthetic peptides strictly formatted for laboratory research use only. All orders are fulfilled directly from state-of-the-art facilities in California and Arizona, offering same-day shipping for orders placed Monday through Friday before cut-off times.
Principal investigators, university departments, and private biotechnology laboratories requiring bulk quantities or recurring lot-reserved orders can establish verified institutional accounts through our wholesale portal. All batches include lot-specific Certificates of Analysis (COA), confirming HPLC purity, mass identity, and rigorous endotoxin limits verified by an independent ISO 17025 accredited laboratory.
Frequently Asked Questions
What is the key structural difference between native IGF-1 and IGF-1 LR3?
IGF-1 LR3 contains an substitution of Glutamic Acid with Arginine at position 3, along with a 13-amino-acid N-terminal extension sequence (totaling 83 amino acids, compared to the 70 amino acids of native IGF-1).
Why does IGF-1 LR3 exhibit an extended half-life in cell culture media?
The structural modifications significantly reduce the binding affinity of IGF-1 LR3 for IGF-Binding Proteins (IGFBP-1 through 6). Because it is not sequestered by IGFBPs, a larger fraction of free peptide remains available to interact with the IGF-1 receptor over prolonged periods.
How is the purity of PX1 Research IGF-1 LR3 verified?
PX1 Research verifies every lot using High-Performance Liquid Chromatography (HPLC) to confirm purity ≥98% and Mass Spectrometry (MS) to confirm exact molecular weight. Testing is performed by independent ISO 17025 accredited laboratories.
What solvent is recommended for initial reconstitution in laboratory protocols?
Lyophilized IGF-1 LR3 is typically reconstituted using a weak acid solution, such as 0.1 M acetic acid or 10 mM HCl (pH 2–3), to ensure complete dissolution and prevent hydrophobic aggregation before diluting into carrier-supplemented buffers.
Are endotoxin levels tested for PX1 Research peptides?
Yes. Every batch undergoes Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain below stringent thresholds (typically <0.01 EU/μg), making them suitable for sensitive cell culture and in vitro applications.
How should reconstituted IGF-1 LR3 solutions be stored for ongoing experiments?
Reconstituted stock solutions stored in weak acid with a carrier protein (such as 0.1% BSA) should be aliquoted and frozen at -20°C or -80°C to prevent degradation from repeated freeze-thaw cycles. Working solutions in neutral media should be used promptly.
How does IGF-1 LR3 compare to IGF-1 DES in binding kinetics?
While both analogs bypass IGFBPs, IGF-1 DES lacks the first three N-terminal residues and exhibits shorter clearance times in systemic models, whereas IGF-1 LR3 features the extended N-terminal sequence that grants longer biological persistence in assay media.
Can research institutions request lot-reserved bulk orders?
Yes. PX1 Research offers institutional supply, custom lot reservation, and volume-based pricing for academic and commercial research laboratories through our wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.